Changing the Natural History of Non-Small-Cell Lung Cancer Through Upfront Programmed Death Protein 1/Programmed Death-Ligand 1 Blockade

被引：4

作者：

Tan, Daniel S. W. ^{[1
]}

机构：

[1] Natl Canc Ctr Singapore, Singapore, Singapore

来源：

JOURNAL OF CLINICAL ONCOLOGY | 2017年 / 35卷 / 24期

关键词：

OPEN-LABEL; 1ST-LINE; IMMUNE; PEMBROLIZUMAB; ATEZOLIZUMAB; CHEMOTHERAPY; CARBOPLATIN; NIVOLUMAB; DOCETAXEL; PHASE-1;

D O I：

10.1200/JCO.2017.73.6215

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

引用

页码：2735 / +

页数：3

共 17 条

[1] Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer [J].

Borghaei, H. ;

Paz-Ares, L. ;

Horn, L. ;

Spigel, D. R. ;

Steins, M. ;

Ready, N. E. ;

Chow, L. Q. ;

Vokes, E. E. ;

Felip, E. ;

Holgado, E. ;

Barlesi, F. ;

Kohlhaeufl, M. ;

Arrieta, O. ;

Burgio, M. A. ;

Fayette, J. ;

Lena, H. ;

Poddubskaya, E. ;

Gerber, D. E. ;

Gettinger, S. N. ;

Rudin, C. M. ;

Rizvi, N. ;

Crino, L. ;

Blumenschein, G. R. ;

Antonia, S. J. ;

Dorange, C. ;

Harbison, C. T. ;

Finckenstein, F. Graf ;

Brahmer, J. R. .

NEW ENGLAND JOURNAL OF MEDICINE, 2015, 373 (17) :1627-1639

[2] Elements of cancer immunity and the cancer-immune set point [J].

Chen, Daniel S. ;

Mellman, Ira .

NATURE, 2017, 541 (7637) :321-330

[3] Molecular Pathways: Immune Checkpoint Antibodies and their Toxicities [J].

Cousin, Sophie ;

Italiano, Antoine .

CLINICAL CANCER RESEARCH, 2016, 22 (18) :4550-4555

[4] Atezolizumab versus docetaxel for patients with previously treated non-small-cell lung cancer (POPLAR): a multicentre, open-label, phase 2 randomised controlled trial [J].

Fehrenbacher, Louis ;

Spira, Alexander ;

Ballinger, Marcus ;

Kowanetz, Marcin ;

Vansteenkiste, Johan ;

Mazieres, Julien ;

Park, Keunchil ;

Smith, David ;

Artal-Cortes, Angel ;

Lewanski, Conrad ;

Braiteh, Fadi ;

Waterkamp, Daniel ;

He, Pei ;

Zou, Wei ;

Chen, Daniel S. ;

Yi, Jing ;

Sandler, Alan ;

Rittmeyer, Achim .

LANCET, 2016, 387 (10030) :1837-1846

[5]

Hellmann MD, 2017, LANCET ONCOL, V18, P31, DOI [10.1016/s1470-2045(16)30624-6, 10.1016/S1470-2045(16)30624-6]

[6] Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial [J].

Herbst, Roy S. ;

Baas, Paul ;

Kim, Dong-Wan ;

Felip, Enriqueta ;

Perez-Gracia, Jose L. ;

Han, Ji-Youn ;

Molina, Julian ;

Kim, Joo-Hang ;

Arvis, Catherine Dubos ;

Ahn, Myung-Ju ;

Majem, Margarita ;

Fidler, Mary J. ;

de Castro, Gilberto, Jr. ;

Garrido, Marcelo ;

Lubiniecki, Gregory M. ;

Shentu, Yue ;

Im, Ellie ;

Dolled-Filhart, Marisa ;

Garon, Edward B. .

LANCET, 2016, 387 (10027) :1540-1550

[7] PD-L1 Immunohistochemistry Assays for Lung Cancer: Results from Phase 1 of the Blueprint PD-L1 IHC Assay Comparison Project [J].

Hirsch, Fred R. ;

McElhinny, Abigail ;

Stanforth, Dave ;

Ranger-Moore, James ;

Jansson, Malinka ;

Kulangara, Karina ;

Richardson, William ;

Towne, Penny ;

Hanks, Debra ;

Vennapusa, Bharathi ;

Mistry, Amita ;

Kalamegham, Rasika ;

Averbuch, Steve ;

Novotny, James ;

Rubin, Eric ;

Emancipator, Kenneth ;

McCaffery, Ian ;

Williams, J. Andrew ;

Walker, Jill ;

Longshore, John ;

Tsao, Ming Sound ;

Kerr, Keith M. .

JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (02) :208-222

[8] Checkpoint Inhibitors in Lung Cancer Are Not Immune from Cost-Effectiveness Analysis [J].

Kelly, Ronan J. ;

Smith, Thomas J. .

JOURNAL OF THORACIC ONCOLOGY, 2016, 11 (11) :1814-1816

[9] Carboplatin and pemetrexed with or without pembrolizumab for advanced, non-squamous non-small-cell lung cancer: a randomised, phase 2 cohort of the open-label KEYNOTE-021 study [J].

Langer, Corey J. ;

Gadgeel, Shirish M. ;

Borghaei, Hossein ;

Papadimitrakopoulou, Vassiliki A. ;

Patnaik, Amita ;

Powell, Steven F. ;

Gentzler, Ryan D. ;

Martins, Renato G. ;

Stevenson, James P. ;

Jalal, Shadia I. ;

Panwalkar, Amit ;

Yang, James Chih-Hsin ;

Gubens, Matthew ;

Sequist, Lecia V. ;

Awad, Mark M. ;

Fiore, Joseph ;

Ge, Yang ;

Raftopoulos, Harry ;

Gandhi, Leena .

LANCET ONCOLOGY, 2016, 17 (11) :1497-1508

[10] Gefitinib or Carboplatin-Paclitaxel in Pulmonary Adenocarcinoma. [J].

Mok, Tony S. ;

Wu, Yi-Long ;

Thongprasert, Sumitra ;

Yang, Chih-Hsin ;

Chu, Da-Tong ;

Saijo, Nagahiro ;

Sunpaweravong, Patrapim ;

Han, Baohui ;

Margono, Benjamin ;

Ichinose, Yukito ;

Nishiwaki, Yutaka ;

Ohe, Yuichiro ;

Yang, Jin-Ji ;

Chewaskulyong, Busyamas ;

Jiang, Haiyi ;

Duffield, Emma L. ;

Watkins, Claire L. ;

Armour, Alison A. ;

Fukuoka, Masahiro .

NEW ENGLAND JOURNAL OF MEDICINE, 2009, 361 (10) :947-957

← 1 2 →